Jaffer A Ajani, Thomas A D'Amico, David J Bentrem, Sakti Chakrabarti, Carlos U Corvera, Prajnan Das, Peter C Enzinger, Thomas Enzler, Hans Gerdes, Michael K Gibson, Patrick Grierson, Garima Gupta, Wayne L Hofstetter, David H Ilson, Shadia Jalal, Ning Jin, Sunnie Kim, Samuel Klempner, Moshim Kukar, Jill Lacy, Vincent Lam, Byrne Lee, Frank Licciardi, Shane Lloyd, Quan P Ly, Karen Matsukuma, Ryan P Merkow, Aaron M Miller, Mary F Mulcahy, Kyle A Perry, Jose M Pimiento, Deepti M Reddi, Scott Reznik, Robert E Roses, Alireza Sedarat, Vivian E Strong, Stacey Su, Nataliya Uboha, Christopher G Willett, Yanghee Woo, Harry H Yoon, Nicole R McMillian, Nicholas Sansone, MaryElizabeth Stein
Esophageal cancer is the seventh leading cause of cancer-related deaths worldwide. Esophageal cancers are histologically classified as squamous cell carcinoma (ESCC) or adenocarcinoma (EAC), which differ in their etiology, pathology, tumor location, therapeutics, and prognosis. In patients with locally advanced or metastatic disease, systemic therapy can provide palliation, improve survival, and/or enhance quality of life. The implementation of biomarker testing and immunotherapy has had a significant impact on clinical practice and patient care. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers highlights current recommendations for advanced ESCC, including the evolving landscape of first-line immunotherapy.